Tags : Biotech


Insights+: Novel Drug Approvals by the US FDA in 2018

1.Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC 2. Helsinn’s (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV) Published: 14 Feb,2018 | Tags: Helsins, fosnetupitant + palonosetron, Receives, FDA, Approval, […]Read More

Biosimilars Insights+

PharmaShots Year in Review: Biosimilars Approvals in 2018

  THE US FDA APPROVALS    1.  Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia Published: 15 May, 2018  | Tags: Pfizer, Retacrit, epoetinalfa-epbx, biosimilar, Receives, FDA, Approval, Anemia   2.   Pfizer’s Nivestym (filgrastim-aafi, biosmilar) Receives FDA Approval forNeutropenia   Published: 20 Jul, 2018 | Tags: (filgrastim-aafi approval biosmilar), Neutropenia, Nivestym, Pfizer, Receives, the […]Read More


PharmaShots Year in Review 2018

 PharmaShots Year in Review | Top 10 Pharma News of 2018  1. Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio Published: 22 Jan, 2018 | Tags: Celgene,  Acquire, Juno, Cellular, Immunotherapy, Hematology Portfolio 2.  Sanofi to Acquire Bioverativ for its Hemophilia Products Published: 22 Jan, 2018 | Tags: Sanofi, Acquire, Bioverativ, Treat, […]Read More


Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Shots: The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, medical affairs, manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months Imetelstat is currently evaluated in […]Read More